Semnur Pharmaceuticals, Inc. (SMNR)

Semnur Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-167.68	-160.42	-4.69	-3.26	-3.77
Stock-Based Compensation	145	142.44	0.66	0.84	0.87
Change in Accounts Payable	3.15	2.15	-	-	-0.78
Change in Other Net Operating Assets	8.85	9.97	-0.86	0.74	-0.37
Operating Cash Flow	-10.54	-5.87	-4.89	-1.68	-4.04
Operating Cash Flow Growth	-	-	-	-	-
Long-Term Debt Issued	-	5.85	4.89	1.66	3.97
Net Debt Issued (Repaid)	8.15	5.85	4.89	1.66	3.97
Other Financing Activities	2.38	0.03	-	-	-
Financing Cash Flow	10.53	5.88	4.89	1.66	3.97
Net Cash Flow	-0.02	0.01	-	-0.02	-0.07
Levered Free Cash Flow	52.03	54.2	-9.11	-0.45	-
Unlevered Free Cash Flow	52.11	54.2	-9.11	-0.45	-
Change in Working Capital	12.01	12.11	-0.86	0.74	-1.15

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 11, 2026

Data Sources Report a data error